Mirna 214 and Progesterone Hormone in Breast Carcinoma

Abstract

Background: MiRNASa (miRNAS) and progesterone have a relationship and role for progesterone receptor in breast cancers in women. Also, endocrine resistance is a problem that makes it hard for treatments to work. Our goal is to find out how the endocrine resistance can be overcome and resistance against progesterone. Method: The samples were taken from Al-Amel National Hospital for Cancer Treatment in Baghdad, Iraq. Their medical records and case sheets were used to find out about them. Samples were taken and split into two groups: Group 1, 25 samples Controls were made up of women who seemed to be healthy and were between the ages of 30 and 70. Group 2: Fifty samples from women with breast cancer who were between the ages of (30-70 years) and stages (I, II, III), patients wereaexcluded at metastasis stage. patients divided to two groups, i) patients had not any treatments after surgery. ii) patients had many treatments after surgery. Results: Association between miR-214 and progesterone have role verified RT-qPCR was used to look at human breast cancer tissue samples to find the direct target of miR-214.The gene expression of miR-214 is shown as mean ± SEM value (1.12 ± 0.08 and 3.56 ± 0.21, respectively) and (p-value < 0.05) revealed a significant positive correlation between the expression level of miRNA214 and progesterone in cancer patients. (Y = 0.28, P = 0.046) Conclusion: MiR-214 increased sensitivity of breast cancer cells to high MiR-214 has the potential to be a new endocrine-busting drug. Technology with excessive high progesterone breast cancer.